Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. develops clinical-stage biopharmaceutical programs for brain diseases and other underserved, prevalent diseases. News for NMRA centers on neuroscience drug development, financial results, business updates, and presentations at healthcare conferences.
Recurring updates describe pipeline programs such as navacaprant for major depressive disorder, NMRA-511 for Alzheimer’s disease agitation, M4 muscarinic receptor positive allosteric modulators including NMRA-861 and NMRA-898, and NMRA-215, an oral brain-penetrant NLRP3 inhibitor. Company announcements also cover clinical study results, development strategy, cash runway commentary, and program prioritization across neuropsychiatric and neurodegenerative disease areas.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on novel mechanisms for prevalent, underserved diseases, will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.
A live webcast and 30-day replay will be accessible via the events and presentations section of the company’s website.
Neumora Therapeutics (NASDAQ: NMRA) reported Q1 2026 results and a business update on May 7, 2026. Key points: KOASTAL‑2 and ‑3 (navacaprant) fully enrolled with a joint topline readout expected in Q2 2026; NMRA‑511, NMRA‑898, and NMRA‑215 have clinical milestones expected in H2 2026–Q1 2027. Cash and cash equivalents were $147.1 million, expected to fund operations into Q3 2027.
Neumora Therapeutics (Nasdaq: NMRA) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 10:15 a.m. ET. A live webcast will stream on the company's events and presentations page, with a replay archived for up to 30 days.
Neumora Therapeutics (Nasdaq: NMRA) reported Q4 and full-year 2025 results and a business update on March 30, 2026. The company finished 2025 with $182.5 million in cash and expects runway into the third quarter of 2027.
Key clinical highlights: KOASTAL-2/-3 fully enrolled (>400 patients each) with joint topline readout expected in Q2 2026; NMRA-511 showed effect sizes of 0.34 (CMAI total) and 0.51 (CMAI aggression) in a 53-patient pre-specified AD agitation cohort; NMRA-898 selected as M4 lead with ~80–100 hour half-life; NMRA-215 toxicology signal under audit and clinical start now targeted Q1 2027.
Neumora Therapeutics (Nasdaq: NMRA) will report fourth quarter and full year 2025 financial results on Monday, March 30, 2026 and will host a conference call and live webcast at 8:00 a.m. ET.
According to Neumora Therapeutics, the live webcast will be available on the company website and a replay will be archived for up to 30 days. Participants are advised to register at least 10 minutes before the call.
Neumora Therapeutics (Nasdaq: NMRA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York.
A live webcast will be available on the company’s events and presentations page and a replay will be archived for up to 30 days.
Neumora Therapeutics (NASDAQ: NMRA) outlined its 2026 pipeline strategy and key near-term milestones, highlighting multiple clinical readouts and program advances. The company expects a joint topline readout for KOASTAL-2 and KOASTAL-3 in Q2 2026 and plans to increase enrollment in each study by up to 25% beyond the original 332 target where protocols allow. Neumora plans to initiate a Phase 1 program for NMRA-215 in H1 2026 with weight-loss data expected around year-end 2026. The company reported positive Phase 1b results for NMRA-511 showing a clinically meaningful effect on AD agitation and no somnolence. Cash runway is expected into Q3 2027.
Neumora Therapeutics (NASDAQ: NMRA) reported positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer’s disease agitation on Jan 5, 2026. Key findings: a reported 15.7-point mean reduction on CMAI total score, larger placebo-adjusted improvements in a pre-specified elevated-anxiety subgroup (placebo-adjusted -7.6 at Week 6, -5.6 at Week 8; Cohen’s d 0.51–0.64), and a favorable tolerability and safety profile with 2.5% discontinuations due to TEAEs. The study was a signal-seeking, not powered for statistical significance. Next steps: multiple ascending dose expansion and formulation work for once-daily extended-release dosing in 2026.
Neumora Therapeutics (NASDAQ: NMRA) reported third-quarter 2025 results and updated pipeline progress on Nov 6, 2025. The company holds $171.5M in cash, cash equivalents and marketable securities and says that funding is expected to support operations into 2027. Neumora drew an additional $40M of non-dilutive capital from its existing K2 HealthVentures facility.
Pipeline milestones: NMRA-215 (oral NLRP3 inhibitor) showed class-leading DIO mouse data and is expected to enter Phase 1 in Q1 2026 with 12-week PoC data in 2026; two M4 PAMs (NMRA-861, NMRA-898) are in Phase 1 with a franchise update planned mid-2026; NMRA-511 Phase 1b data for AD agitation is on track around year-end; navacaprant KOASTAL topline readouts expected in Q1 and Q2 2026.
Neumora Therapeutics (Nasdaq: NMRA) will participate in two investor conferences in November 2025. Management will take part in fireside chats at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 2:30 p.m. ET in Boston and at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:00 p.m. ET in New York.
A live webcast of both events will be available on the company's events and presentations webpage at www.neumoratx.com, with replays archived for up to 30 days after the events.